Cerity Partners LLC Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cerity Partners LLC boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 16,060 shares of the biopharmaceutical company’s stock after buying an additional 512 shares during the quarter. Cerity Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $12,576,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently bought and sold shares of REGN. Federated Hermes Inc. lifted its position in shares of Regeneron Pharmaceuticals by 535.5% in the fourth quarter. Federated Hermes Inc. now owns 35,963 shares of the biopharmaceutical company’s stock valued at $25,618,000 after acquiring an additional 30,304 shares in the last quarter. Peapack Gladstone Financial Corp lifted its position in shares of Regeneron Pharmaceuticals by 26.3% in the fourth quarter. Peapack Gladstone Financial Corp now owns 2,839 shares of the biopharmaceutical company’s stock valued at $2,021,000 after acquiring an additional 591 shares in the last quarter. Ilmarinen Mutual Pension Insurance Co lifted its position in shares of Regeneron Pharmaceuticals by 42.5% in the fourth quarter. Ilmarinen Mutual Pension Insurance Co now owns 11,400 shares of the biopharmaceutical company’s stock valued at $8,121,000 after acquiring an additional 3,400 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of Regeneron Pharmaceuticals by 6.1% in the fourth quarter. Russell Investments Group Ltd. now owns 137,208 shares of the biopharmaceutical company’s stock valued at $97,690,000 after acquiring an additional 7,944 shares in the last quarter. Finally, Wedbush Securities Inc. lifted its position in shares of Regeneron Pharmaceuticals by 6.8% in the fourth quarter. Wedbush Securities Inc. now owns 843 shares of the biopharmaceutical company’s stock valued at $600,000 after acquiring an additional 54 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

REGN has been the topic of several research analyst reports. Sanford C. Bernstein lowered their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Bernstein Bank lowered their price objective on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Robert W. Baird reduced their target price on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a report on Wednesday, February 5th. Truist Financial dropped their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. Finally, Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $966.88.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $576.72 on Thursday. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $525.99 and a 12 month high of $1,211.20. The company has a market capitalization of $63.05 billion, a price-to-earnings ratio of 15.07, a PEG ratio of 2.34 and a beta of 0.44. The firm’s 50-day moving average is $665.21 and its 200 day moving average is $762.01.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the prior year, the firm posted $11.86 earnings per share. The company’s quarterly revenue was up 10.3% on a year-over-year basis. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.61%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.